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Two lines of evidence suggest that the Sry-related gene Sox9 is important for chondrogenesis in mammalian embryos.
Sox9 mRNA is expressed in chondrogenic condensations in mice, and mutations in human SOX9 are known to cause
skeletal dysplasia. We show here that mouse SOX9 protein is able to bind to a SOX/SRY consensus motif in DNA and
contains a modular transcriptional activation domain, consistent with a role for SOX9 as a transcription factor acting on
genes involved in cartilage development. One such gene is Col2a1, which encodes type II collagen, the major structural
component of cartilage. We have compared, in detail, the expression of Sox9 and Col2a1 during mouse development. In
chondrogenic tissues the expression pro®les of the two genes were remarkably similar. Coexpression was detected in some
nonchondrogenic tissues such as the notochord, otic vesicle, and neural tube, but others such as heart and lung differed
in their expression of the two genes. Immunohistochemistry using an antibody speci®c for SOX9 revealed that expression
of SOX9 protein mirrored the distribution of Sox9 mRNA. Our results suggest that SOX9 protein is involved in the
regulation of Col2a1 during chondrogenesis, but that this regulation is likely to depend on additional cofactors.
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INTRODUCTION Sox9 is a recently identi®ed gene that may have a role in
regulating chondrogenesis in mammals. This gene encodes
During the development of the vertebrate skeleton, endo- one of a family of proteins that includes the mammalian Y-
chondral bone formation is initiated when mesenchymal linked testis-determining factor, SRY (Gubbay et al., 1990).
cells condense and differentiate to form chondrocytes. Several SOX proteins have been shown to bind to DNA and
These cells synthesize a framework of cartilage matrix in activate transcription in vitro (van de Wetering et al., 1993;
the approximate shape of future bones. The recent identi®- Dubin and Ostrer, 1994; Hosking et al., 1995; Kamachi et
cation of gene defects responsible for skeletal abnormalities al., 1995; Kanai et al., 1996). This property and the tissue-
in mouse and man has shown that not only structural com- speci®c expression pattern of some Sox genes (Koopman et
ponents of the cartilage extracellular matrix, but also al., 1990; Stevanovic et al., 1993; van de Wetering et al.,
growth and differentiation factors, signaling molecules, and 1993; Uwanogho et al., 1994; Connor et al., 1995; Dunn et
transcription factors are important for proper morphogene- al., 1995; Hosking et al., 1995; Jay et al., 1995; Kamachi et
sis during skeletal development (reviewed by Erlebacher et al., 1995; Kanai et al., 1996) indicate that they may regulate
al., 1995). However details of the mechanisms involved and gene expression in speci®c cell lineages. A preliminary sur-
the identities of many of the interacting molecules regulat- vey in which Sox9 expression was examined in whole-
ing chondrogenesis remain unknown. mount mouse embryos has shown this gene to be expressed
strongly in mesenchymal condensations before and during
chondrogenesis, and in other tissues such as the central1 These two authors contributed equally to this work.
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TABLE 1
Primers Used in the Construction of Sox9 Deletion Mutants
Construct Primers (5*±3*) Primer positiona
pGSox9p Sox9A1 (GCGAATTCATGAATCTCCTGGACCCCTT) 302±321
g10b (TTCCGTGGCCTCTTCGGCCTC) 863±882
pGR990 Sox9A3 (GGGAATTCGTGAAGAACGGACAAGCGG) 845±863
Sox9B2 (CTTCTAGAAGGGTCTGGTGACCTGTGT) 1823±1805
pGR560 Sox9A2 (CCGAATTCGCGACCGCGGGCCACG) 1286±1301
Sox9B2
pGR300 Sox 9A2
Sox9B1 (AGTCTAGATGAAGGGGCTGTAGGAGAT) 1565±1547
pGR260 Sox9A4 (ACGAATTCCACTACAGGCCCTCCTAC) 1574±1591
Sox9B2
a Position shown relative to Sox9 cDNA sequence described by Wright et al. (1995).
nervous system, otocysts, heart, and vibrissae (Wright et (Garofalo et al., 1991; Vandenberg et al., 1991; MetsaÈranta
et al., 1992; Li et al., 1995).al., 1995). The human SOX9 gene is also expressed in differ-
In this study we show that SOX9 protein can bind to aentiating chondrocytes, and mutation of the gene is associ-
SOX/SRY consensus sequence, copies of which are presentated with the skeletal malformation disorder campomelic
in the regulatory regions of the human COL2A1 gene. Indysplasia (CD; Foster et al., 1994; Wagner et al., 1994).
addition, we identi®ed a modular activation domain in theTo delineate the potential role of Sox9 in cartilage and
protein, suggesting a role for SOX9 as a transcriptional acti-bone development, it is important to determine its func-
vator. Further, we have compared in detail the timing andtional properties and identify molecules with which it may
sites of expression of the Sox9 and Col2a1 genes duringinteract. The timing and sites of Sox9 expression during
mouse embryogenesis. We show, by in situ hybridization,mouse development (Wright et al., 1995), and the skeletal
a concordance of expression of these two genes at sites ofdysmorphology associated with SOX9 mutations in CD pa-
chondrogenesis, consistent with a role for Sox9 as a directtients (Lee et al., 1972; Hovmoller et al., 1977; Houston et
or indirect regulator of Col2a1.al., 1983; Foster et al., 1994; Wagner et al., 1994), indicate
that a major function of SOX9 is to regulate a gene or genes
important for chondrocyte differentiation and skeletal de-
velopment. Candidates include genes expressed early in MATERIALS AND METHODS
chondrocyte differentiation, such as those encoding carti-
lage extracellular matrix components (e.g., collagens, pro- Cloning of Sox9 Deletion Mutants
teoglycans, cartilage matrix protein, and cartilage oligo-
A construct (pGSox9p) containing the Sox9 open reading framemeric matrix protein), growth factors (e.g., ®broblast growth
and the 3* untranslated region was cloned as a fusion of a 583-bp
factors, bone morphogenetic proteins, cartilage-derived PCR fragment generated using the primers Sox9A1 and g10b (Table
growth factors, and parathyroid hormone-related peptide) 1) and a 1.6-kb BssHII/XhoI fragment of Sox9 cDNA (Wright et al.,
and their receptors, signaling molecules (e.g., members of 1995) into the expression vector pGAL0 (Kato et al., 1990). Sox9
the hedgehog family), and other transcription factors. deletion mutants were generated by cloning PCR fragments gener-
ated from the Sox9 cDNA in frame into the same vector. PCRThe major extracellular matrix component of cartilage is
primers used for this purpose are described in Table 1. Inserts oftype II collagen, which constitutes up to 60% of the total
constructs other than pGR990 were sequenced completely, andprotein content. Type II collagen is a homotrimer of identi-
all insert/vector junctions were sequenced using a GAL4-speci®ccal a1(II) chains, encoded in the mouse by the Col2a1 gene.
primer (5*-CGACATCATCATCGGAAGAG-3*) to verify the read-
Transcription of Col2a1 in mesenchymal cells precedes ing frame.
chondrocyte differentiation and is one of the hallmarks of
chondrogenesis (von der Mark and von der Mark, 1977;
Kravis and Upholt, 1985; Kosher et al., 1986; Swalla et al., Electrophoretic Mobility Shift Assay (EMSA)
1988, Cheah et al., 1991; Ng et al., 1993). Type II collagen
To generate a source of SOX9 protein suitable for EMSA analysis,is important in maintaining the integrity of cartilaginous
20 mg of a plasmid containing the coding sequence for the ®rst 147structures, and disruptions of its synthesis due to mutations
amino acids of the yeast transcriptional activator GAL4 (GAL0;
of the COL2A1 gene have been linked to human chondro- Kato et al., 1990) fused to the Sox9 coding sequence (Wright et al.,
dysplasias (reviewed by Vikkula et al., 1994; Ritvaniemi et 1995) was transfected into COS-1 cells using Lipofectamine (Gibco
al., 1995). Abnormal skeletal formation is also found in BRL) as described (Kent et al., 1996). Nuclear extracts were prepared
from GAL0-transfected and GALSOX9-transfected cells using atransgenic mice that express mutated type II collagen genes
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FIG. 1. DNA binding and transcriptional activation by SOX9 protein. (A) SOX9 binds to the SOX/SRY consensus AACAAT. EMSA
analysis: lane 1, an extract from GAL0-transfected COS-1 cells incubated with the probe does not produce a speci®c retarded band; lane
2, an extract from GALSOX9-transfected cells produces a retarded band speci®c for SOX9; lane 3, the identity of the SOX9 band is
con®rmed using anti-SOX9 polyclonal antiserum, which produces a ``supershift''; lane 4, this supershift is abolished by incubating the
probe, extract, and antibody with the immunogenic peptide which competes for binding to the antibody and prevents it binding to SOX9
and producing the supershift. The positions of the SOX9 band and the ``supershifted'' band are indicated. (B, C) Activation of transcription
by SOX9. (B) Constructs for GAL4 transcriptional activation assays containing the full-length Sox9 open reading frame or fragments
thereof fused to the GAL4 DNA-binding domain. (C) The extent of transcriptional activation by each construct is indicated by the CAT
assay results and the mean of triplicate assays is shown with bars indicating standard error.
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FIG. 2. Whole-mount in situ hybridization of 12.5 dpc fetuses showing the similarity of expression of Sox9 (A) and Col2a1 (B) in skeletal
structures.
method based on that described by Osborn et al. (1989). Brie¯y, (Boehringer-Mannheim). Between 40 and 48 hr after transfection,
cells were harvested and the ability of SOX9 to activate transcrip-after washing the cells in buffer A, 107 cells were resuspended in
500 ml buffer A and 1 ml buffer A/0.1% NP-40 was added. After tion was assayed by measuring CAT activity (Gorman et al., 1982).
Constructs were assayed in three independent experiments.mixing gently, nuclei were collected by centrifugation at 2500 rpm
for 3 min at 47C in a microfuge and then resuspended in 100 ml
buffer C. After vortexing, incubation on ice for 10 min, and centrif-
In Situ Hybridizationugation at 13,000 rpm for 10 min at 47C in a microfuge, the superna-
tant containing nuclear proteins was stored at 0707C. Binding reac-
Antisense and sense probes for in situ hybridization were gener-tions (Schreiber et al., 1989) were performed in the presence of 2
ated from clones pNJ61, pEL111, and pSox9.5a. pNJ61 is a 500-bpmg salmon sperm DNA and 1 mg/ml BSA. An extract from GAL0-
fragment covering exon 1 to exon 5B of Col2a1 obtained by RT-transfected cells was used as a background DNA-binding activity
PCR using oligonucleotides 5*-TCTCCTGCCTCCTCCTGCTC-3*control. Brie¯y, 4 mg of nuclear extract was incubated initially with
and 5*-CTCCATCTCTGCCACGGGGT-3* subcloned in pBlue-all components except probe for 30 min on ice. After the addition
scribe (Stratagene). pEL111 is a 0.6-kb genomic fragment of Col2a1of 1 ng gel-puri®ed, double-stranded probe (sense strand: 5*-GAT-
containing exon 1 (Cheah et al., 1991). pSox9.5a (Wright et al.,CCGGACTAATAAACAATAAAGTCGACG-3*), the reactions
1995) contained 500-bp of sequence 3* to the HMG box of Sox9 notwere incubated on ice for a further 30 min and loaded onto a nonde-
including the poly(A) sequence, subcloned in pBSKSII0 (Stratagene).naturing 5% polyacrylamide, 0.81TBE gel. Sixteen-centimeter gels
Whole-mount in situ hybridization was carried out using 12.5were run at 10 V/cm and the dried gels were exposed to Fuji RX
days post coitum (dpc) Swiss outbred mouse embryos as describedX-ray ®lm. Variations to this standard procedure included adding
by Wright et al. (1995), using pSox9.5a and pEL111 probes. For in0.5 mg af®nity-puri®ed anti-SOX9 polyclonal antiserum (Kent et
situ hybridization to sections, CBA/n mouse embryos at 7.5 to 18.5al., 1996) or adding antibody plus 1 mg of the immunogenic SOX9
days were ®xed in 4% paraformaldehyde and processed as describedpeptide.
(Cheah et al., 1991). pNJ61 and pSox9.5a RNA probes labeled with
[a-35S]UTP (1000 Ci/mmol, Amersham) were generated by in vitro
transcription and used to localize transcripts in embryonic tissues.Transfection of Mammalian Cells and
The number of UTP molecules per strand of antisense RNA probeChloramphenicol Acetyl Transferase (CAT) Assays
generated from pNJ61 and pSox9.5a are 110 and 119, respectively;
therefore, the intensities of hybridization signals of the two ribo-COS-1 cells at 60±70% con¯uence were transiently transfected
with 1.5 mg of chimeric GAL4-Sox9 plasmids and 3.5 mg of reporter probes are comparable. pNJ61 and pSox9.5a were hybridized to con-
secutive adjacent sections covering 24±48 mm. Speci®c hybridiza-plasmid (pG5E1bCAT, containing ®ve GAL4 binding sites up-
stream of the CAT gene) per well of a six-well plate, using DOTAP tion was achieved by treating the sections with 20 mg/ml RNase
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FIG. 3. Coexpression of Sox9 and Col2a1 in the early embryo and chondrogenic tissues. Sox9 expression is shown in A, C, E, G, I, K,
and M (left-hand side of each pair of photomicrographs) and Col2a1 in B, D, F, H, J, L, and N (right-hand side of each pair). Each pair of
illustrations was taken from sections approximately 24±48 mm apart within the same specimen. (A) Sox9 expression in the notochordal
plate (n) at 7.5 dpc. (B) 7.5 dpc embryo hybridized with Col2a1 probe showing expression limited to a small patch of primitive endoderm
Copyright q 1997 by Academic Press. All rights of reproduction in any form reserved.
AID DB 8487 / 6x1a$$8487 02-13-97 11:56:33 dbal
113Coexpression of Sox9 and Col2a1
A and 50 u/ml RNase T1 at 377C for 45 min and washing at 657C COL2A1 gene (MetsaÈ ranta et al., 1991), suggesting that it
in 21 SSC, 50% formamide, 20 mM dithiothreitol. Autoradiogra- might mediate binding of SOX9 to this gene and activate
phy and photography of sections were as described previously transcription. EMSA analysis was carried out to investigate
(Cheah et al., 1991). whether SOX9 can bind to this consensus. Speci®c binding
activity with this probe was observed with extracts of GAL-
SOX9-transfected COS-1 cells, but not with extracts ofImmunohistochemistry
GAL0-transfected cells (Fig. 1A). The identity of the SOX9-
Immunohistochemistry was performed on frozen sections of speci®c band was con®rmed by including af®nity-puri®ed
mouse embryos. Embryos were dissected into PBS, ®xed in 4% anti-SOX9 polyclonal antiserum (Kent et al., 1996) in some
paraformaldehyde for 4 hr or overnight at 47C, and saturated with
binding reactions. This produced a ``supershift'' of the SOX915% glucose in PBS overnight at 47C. After incubation in graded
band, which was abolished by incubating the binding reac-mixtures of 15% glucose/PBS and OCT compound (Tissuetek), em-
tion plus antibody with the immunogenic peptide used tobryos were embedded in OCT in cryomoulds (Tissuetek) and frozen
raise the antibody (Fig. 1A). These results demonstrate thaton dry ice for 30 min. Ten-micrometer sections were cut on a
cryostat at 0207C. Sections were applied to SuperFrost/Plus slides SOX9 binds to the consensus sequence AACAAT.
(Menzel Glaser, Germany) and allowed to dry thoroughly before Eukaryotic transcription factors usually consist of modu-
staining. lar DNA binding and transcriptional activation or repres-
All steps in the staining procedure were performed in a humidi- sion domains (Ptashne, 1988; Mitchell and Tjian, 1989).
®ed chamber at 47C. Sections were ®rst rinsed 21 with PBS then Consistent with a role as a transcriptional activator, the
bleached with 0.6% H2O2 in PBS for 20 min. Sections were then SOX9 protein contains two domains which are rich in pro-blocked with 10% fetal calf serum/0.1% Triton X-100 in PBS for 30
line, glutamine, or serine residues and which are distinctmin. The speci®city of the anti-SOX9 antibody has been established
from the HMG box DNA binding domain (Wright et al.,previously (Kent et al., 1996). Af®nity-puri®ed anti-SOX9 antise-
rum was diluted to 10 mg/ml in PBS/Triton X-100 and applied to 1995). To determine whether SOX9 is able to activate tran-
the sections overnight. The sections were then washed in PBS/ scription and to de®ne the domains of activation, distinct
Triton X-100 and a biotinylated anti-rabbit Ig (Amersham) was di- SOX9 protein domains were assayed using the GAL4 hybrid
luted to 10 mg/ml and applied to the sections overnight. After wash- system in transfected mammalian cells (Lillie and Green,
ing in PBS/Triton X-100 then PBS alone, a horseradish peroxidase 1989).
(HRP)-conjugated avidin/biotin complex (ABC) reagent (Vector Lab-
A full-length SOX9 construct (pGSox9p; Fig. 1B) was ableoratories) was applied to the sections for 30 min. After washing in
to activate transcription, albeit weakly (Fig. 1C), raising thePBS, HRP was developed using 2.5 mg/ml 3,3*-diaminobenzidine,
possibility that the presence in this construct of a second0.08% NiCl2 , and 0.03% H2O2 . Sections were dehydrated, cleared,
DNA binding domain, the HMG box, affected the assay. Toand mounted in DPX mounting medium. Photomicrographs were
taken on an Olympus AX70 microscope using Kodak 64T Ekta- examine this possibility, the HMG box was excluded by
chrome ®lm. assaying only the 3* coding sequence (pGR990; Fig. 1B).
This construct was able to stimulate the transcription of
the reporter gene to a very high level (Fig. 1C), indicating
RESULTS that SOX9 contains at least one activation domain down-
stream of the HMG box.
SOX9 Can Bind DNA and Is a Transcriptional Further experiments were performed to delimit the acti-
Trans-Activator vation domain(s). A region exceptionally rich in proline and
glutamine residues (amino acids 329±421) was consideredThe sequence AACAAT has been determined as the opti-
most likely to be responsible for the transcriptional activa-mal binding site for SRY (Harley et al., 1994), SOX5 (Denny
tion, by analogy with the composition of activation do-et al., 1992), and SOX17 (Kanai et al., 1996), and it has been
mains in the B-cell-speci®c factor OTF-2 (Clerc et al., 1988),shown that this sequence can bind SOX2 (Kamachi et al.,
the human Sp1 transcription factor (Courey and Tjian,1995) and SOX6 (Connor et al., 1995). Copies of this se-
quence are present in the regulatory regions of the human 1988), and members of the CTF/NF-I family (Santoro et al.,
cells in the anterior region (en). (C, D) Expression of both genes is detected in the cranial paraxial mesenchyme (pm) and notochord (nd)
of 8.5 dpc embryos (see also coexpression in 9.5 dpc notochord, Figs. 6A and 6B). The in situ hybridization signal for Sox9 transcripts is
strong in the crest of the neural plate (nc), the surface ectoderm (se, presumptive placodal epithelium), and the subjacent neural crest
cells (C). Cardiogenic mesoderm (ht) shows strong Col2a1 expression (D). (E, F) Coexpression in the sclerotome (sc) of the lower trunk
somites of a 9.5 dpc embryo. Weaker Sox9 expression is found in the dermamyotome (dm). (G, H) Mesenchymal condensation for
prevertebrae (pv) expresses both Sox9 and Col2a1 mRNAs. Strong Sox9 expression is found in the urogenital ridge (gr) of this 11.5 dpc
embryo (sex unknown). (I, J) Expression of Sox9 and Col2a1 in the chondrogenic mass of the tarsals and metatarsals in the hind limb of
a 15.5 dpc fetus. The arrows point distally. (K, L) Coexpression of both genes in the chondrocytes of the lower trunk vertebrae (vb) of a
14.5 dpc embryo and diminished level of expression in the intervertebral tissues (arrowheads). (M, N) Relatively stronger expression of
Col2a1 compared to Sox9 in the proliferating chondrocytes of the basioccipital bone at 16.5 dpc. In hypertrophic chondrocytes (hc) Col2a1
mRNAs were diminished and Sox9 transcripts were almost at background levels. Bar  50 mm (A±D) and 100 mm (E±N).
Copyright q 1997 by Academic Press. All rights of reproduction in any form reserved.
AID DB 8487 / 6x1a$$$101 02-13-97 11:56:33 dbal
114 Ng et al.
1988). Present within this region is a stretch of 39 amino
acids composed exclusively of proline (15), glutamine (17),
and arginine residues (7). Surprisingly, this region was able
to transactivate only weakly (pGR300; Figs. 1B and 1C).
Instead, the C-terminal fragment (pGR260, amino acids
424±507; Fig. 1B) was able to stimulate transcription to a
very high level, comparable to the strong transcriptional
activators SOX18 (Hosking et al., 1995; Fig. 1C) and Sp1
(Courey and Tjian, 1988; data not shown). These results
demonstrate the presence of a potent modular activation
domain within the terminal 83 amino acids of the SOX9
protein.
Sox9 and Col2a1 Are Coexpressed in Skeletogenic
Tissues
A comparison of the distribution of the Sox9 and Col2a1
transcripts by whole-mount in situ hybridization of midges-
tation mouse fetuses revealed a widespread concordance of
gene expression in cartilaginous tissues (Fig. 2). Expression
of these two genes was examined in detail by in situ hybrid-
ization on sections of mouse embryos of various stages.
The presence of SOX9 protein was con®rmed at many Sox9
mRNA expression sites by immunohistochemistry on cryo-
sections of mouse embryos. Coexpression of Sox9 and
Col2a1 was ®rst noted in the cranial mesenchyme of em-
bryos at the early somite stage (8.5 dpc). Sox9 was expressed
strongly in the mesenchyme subjacent to the surface ecto-
derm and the epidermal placodes at the mid- and hindbrain
level, which presumably consists of migrating neural crest
cells that contribute to the facial skeleton (Fig. 3C). Moder-
ate expression was also found in the paraxial mesoderm
(Fig. 3C). Col2a1 expression in the cranial mesenchyme was
mostly con®ned to the paraxial mesoderm with lower levels
of expression in the neural crest cell population (Fig. 3D).
Both Sox9 and Col2a1 were expressed at later stages in the
frontonasal mesenchyme, cranial paraxial mesenchyme, FIG. 4. Immunohistochemical analysis of SOX9 protein expres-
branchial arch mesenchyme, and the dispersing sclerotome sion. (A) A transverse section of a 10.5 dpc mouse embryo. SOX9
protein is present in the notochord (nd), the sclerotome (sc) of theof the somites (Figs. 3E and 3F). SOX9 protein was also
somites and the ventricular neuroepithelial layer of the spinal cordobserved in the dispersing sclerotome of the somites at 10.5
(vne). (B) A parasagittal section of a 13.5 dpc mouse embryo showingdpc (Fig. 4A).
SOX9 protein in the prevertebrae (pv). The SOX9-expressing noto-Sox9 and Col2a1 were strongly expressed when the pre-
chord (nd) is also seen, while the dorsal root ganglia (dg) betweenchondrogenic mesenchyme condensed into cartilage pri-
the prevertebrae are negative. SOX9 is also expressed in the mesen-
mordia throughout the developing skeleton (Fig. 2). For ex- chymal condensations of the laryngeal cartilages (lc). (C) A parasag-
ample, the prevertebrae derived from the condensation of ittal section through a 13.5 dpc embryo, more lateral to that in
sclerotomal cells clearly expressed both genes (Figs. 3G and B, showing SOX9 expression in the vertebral bodies undergoing
3H) and SOX9 protein expression was also con®rmed in chondrocytic differentiation, but not yet hypertrophy. (D) High-
these structures (Figs. 4B and 4C). Transcription of both power view showing the strong expression of SOX9 in proliferating
chondrocytes from a hind limb bone of a 17.5 dpc embryo. Arrowsgenes and expression of SOX9 protein (Fig. 4D) were main-
show SOX9 protein in the nuclei of these cells. (E) High-powertained as the prechondrocytes differentiated into immature
view of hypertrophic chondrocytes from the same bone as in D,and proliferating chondrocytes. In situ hybridization re-
showing that the expression of SOX9 protein is downregulatedvealed the presence of Sox9 and Col2a1 mRNAs in the peri-
upon hypertrophy of the chondrocytes. (F) A parasagittal sectionchondrium and the pre-hypertrophic chondrocytes of fetal
through a 10.5 dpc embryo showing that SOX9 is expressed in the
cartilages such as the hind limb cartilages (Figs. 3I and 3J), epithelium of the otic vesicle (ov). (G) A parasagittal section of a
vertebral bodies (Figs. 3K and 3L), cartilage in the skull, 10.5 dpc embryo showing SOX9 protein in the endocardial cushions
larynx, sternum, limb girdles, and Meckel's cartilage. Both of the developing heart (ec) ¯anking the atrioventricular canal (av).
transcripts and SOX9 protein were absent or at very dimin- SOX9 protein is absent from the epimyocardium (epm). Bar  100
ished levels in hypertrophic chondrocytes in the centrum mm (A, B), 50 mm (C, F, G), and 25 mm (D, E).
Copyright q 1997 by Academic Press. All rights of reproduction in any form reserved.
AID DB 8487 / 6x1a$$$101 02-13-97 11:56:33 dbal
115Coexpression of Sox9 and Col2a1
FIG. 5. Summary of the expression pro®les of Sox9 and Col2a1 in skeletal and nonskeletal tissues during mouse development.
of the vertebrae and in the preossi®ed regions of the carti- Sox9 and Col2a1 Are Coexpressed in a Subset of
Nonskeletal Tissueslage in the chondrocranium, ribs, otic capsule, and limb
bones (Figs. 3M and 3N, 4E, and data not shown). From 13.5
The concordant expression of Sox9 and Col2a1 mRNA
dpc onward, expression of Sox9 and Col2a1 was also found and SOX9 protein was not found exclusively in chondro-
in some osteogenic tissues of membranous bones such as genic and osteogenic tissues. Coexpression was also ob-
the cranium and the facial and jaw skeleton. Sox9 mRNAs served in the notochord and otic vesicles and at speci®c
were concentrated mostly in the endocranium in contrast stages of central nervous system (CNS) development. In
with the more uniformly distributed Col2a1 transcripts. general, as in skeletogenic tissues, Col2a1 was activated at
During late fetal development (17.5±18.5 dpc), Sox9 expres- the same stage as or shortly after Sox9, and Col2a1 expres-
sion progressively diminished in most skeletal tissues and sion tended to persist beyond the extinction of Sox9.
by 18.5 days, Sox9 expression was found only in small clus- Notochord. Sox9 mRNA was ®rst detected in the node,
ters of chondrocytes in the femur, vertebral bodies, larynx, the early notochordal plate, and the mesoderm immediately
and some osteoblasts in the mandible and maxilla. Col2a1 lateral to the node of the late primitive streak-stage embryo,
expression continued during this period. before the onset of expression of Col2a1 (Figs. 3A and 3B).
In summary, coexpression of Sox9 and Col2a1 mRNA Expression of Col2a1 lagged behind that of Sox9 and was
and of SOX9 protein was observed during the differentiation ®rst detected in the nascent notochord of the early-somite-
and maturation of chondrocytes and osteogenic tissues (Fig. stage embryo (8.5 dpc; Fig. 3D). Sox9 and Col2a1 were coex-
5). However, during late fetal development, Sox9 mRNA pressed in the notochord until 12.5 dpc (Figs. 3C and 3D,
and protein expression in mature cartilage and membranous 4A and 4B, 5, and 6A and 6B), after which time Sox9 tran-
scripts were not detected. However, SOX9 protein expres-bones is downregulated in advance of Col2a1.
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sion was con®rmed in the notochord at 10.5 and 13.5 dpc genes was seen in the heart. At early somite stage (8.5 dpc),
Sox9 transcripts were absent when Col2a1 was expressed(Figs. 4A and 4B), demonstrating that SOX9 protein expres-
sion persisted beyond that of Sox9 mRNA. strongly in the cardiogenic mesoderm (Figs. 3C and 3D).
Sox9 expression was found during the differentiation of theOtic vesicles. Expression of Sox9 was ®rst detected in
the epidermal placodes that precede the invagination of the heart tissues and was restricted initially to the thin layer
of endocardium in the atrium at 9.5 dpc. Subsequently, atotic vesicle (Fig. 3C). Once invagination has occurred, both
Sox9 and Col2a1 mRNA and SOX9 protein were expressed 11.5 and 12.5 dpc Sox9 was found in the endocardium of
the heart chambers, in the endocardial cushions of the heartin the epithelium of the vesicles (Figs. 4F and 6C and 6D).
In contrast to Col2a1, Sox9 transcripts were not detected valves, and in the atrioventricular canal (Fig. 6G). Differen-
tial expression of these genes was con®rmed by the observa-in the sensory epithelium of the inner ear at 11.5±17.5 dpc
(data not shown). tion that SOX9 protein is expressed only in the endocardial
cushions of the heart at 10.5 dpc (Fig. 4G). In contrast,Central nervous system. Sox9 and Col2a1 were ex-
pressed in different dorsoventral regions of the early neural Col2a1 was expressed in the epimyocardium of the heart
(Fig. 6H). Expression of Col2a1 was transient and was absenttube, but came to be coexpressed in later stages of CNS
development. Sox9 was ®rst expressed in the crest region by 14.5 dpc. However, weak expression of Sox9 mRNA
persisted in the endocardial cushion of the heart as lateof the cephalic neural plate at 8.5 dpc (Fig. 3C). In the closed
neural tube, Sox9 expression was strongest in the roof plate as 16.5 dpc.
and the alar plate (Fig. 6A), and Col2a1 expression was gen-
erally low (Fig. 6B). Coexpression of these genes was found
in the neuroepithelium of the forebrain at 8.5±9.5 dpc. At DISCUSSION
later stages (10.5±16.5 dpc), Sox9 and Col2a1 were coex-
pressed in the ventricular layer of the forebrain, midbrain,
The human and mouse SOX9/Sox9 genes encode highlyand hindbrain (Figs. 6E and 6F) and in the roof plate of the
conserved proteins with features of transcriptional regula-lower hindbrain and cervical spinal cord. SOX9 protein was
tors, including potential DNA binding and transcriptionalalso detected in the ventricular neuroepithelial layer of the
activation domains (Foster et al., 1994; Wagner et al., 1994;spinal cord (Fig. 4A). Expression of Sox9 was extinguished
Wright et al., 1995). The ability to activate transcriptionby 15.5±16.5 dpc but Col2a1 transcripts persisted in the
has been demonstrated for the mouse proteins SRY, SOX2,hindbrain neuroepithelium.
SOX4, SOX17, and SOX18 (van de Wetering et al., 1993;
Dubin and Ostrer, 1994; Hosking et al., 1995; Kamachi et
al., 1995; Kanai et al., 1996), but it is not yet known whetherDifferential Expression of Sox9 and Col2a1
this is a general feature of SOX proteins. We have demon-
strated that mouse SOX9 protein can activate transcriptionDespite extensive coexpression of Sox9 and Col2a1 dur-
ing development, particularly in skeletogenic tissues, many of a reporter gene in mammalian cells. Unexpectedly, the
strongest transactivation domain for SOX9 was located inexamples of differential expression of the two genes were
found in other fetal tissues at various stages. These are sum- the C-terminal 83 amino acid residues and not in the pro-
line- and glutamine-rich domain typical of several knownmarized in Table 2 and Fig. 5. In some mesoendodermal
organs, Sox9 and Col2a1 were expressed in tissue types de- transcription factors. Our data con®rm and extend those of
SuÈ dbeck et al. (1996) who demonstrated that the carboxy-rived from different germ layers. For example, Sox9 was not
expressed in the endoderm of the pharynx where Col2a1 terminal 107 amino acids of human SOX9 can activate tran-
scription. As the human and mouse SOX9 proteins showwas expressed. In the respiratory tract, Sox9 was expressed
in the bronchial epithelium and the mesenchyme of the an overall amino acid identity of 96%, it is assumed that
the two proteins are biochemically and functionally indis-lung bud but Col2a1 transcripts were found only in the
bronchial epithelium and not in the mesenchyme at 12.5 tinguishable. It will be of interest to delimit further the
region required for transcriptional activation. In this regarddpc. A striking example of differential expression of the two
FIG. 6. Expression of Sox9 and Col2a1 in nonchondrogenic tissues. Sox9 expression is shown in A, C, E, and G (left-hand side picture
of each pair) and Col2a1 in B, D, F, and H (right-hand side pictures). (A, B) Sox9 transcripts are localized to the dorsal region of the neural
tube (nt) of a 9.5 dpc embryo and in the sclerotome of the somites (sm), whereas Col2a1 expression is low in the neural tube but strong
in the sclerotome. The notochord (nd) expresses both genes. (C, D) Coexpression in the otic vesicle (ov) at 9.5 dpc. Note the relatively
weaker expression of Sox9 in the paraxial mesoderm (pm). (E, F) Coexpression of both genes in the ventricular neuroepithelium (vne) of
the hindbrain and the roof plate (arrows) of an 11.5 dpc embryo. IV marks the fourth ventricle of the hindbrain. (G, H) Differential
expression of Sox9 and Col2a1 in the 11.5 dpc heart. Sox9 is expressed in the endocardium (arrowhead) of the ventricle and in the
endocardial cushions (ec) ¯anking the atrioventricular canals (av). Col2a1, in contrast, is expressed in the epimyocardium (epm) of the
ventricular and the interatrial region. Strong expression of both genes is found in the pharyngeal mesenchyme (phm) but Col2a1 is
preferentially expressed in the pharyngeal pouch (pp) and the arch mesenchyme adjacent to the arch artery (aa). Bar  50 mm (A, B, G, H)
and 100 mm (C±F).
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TABLE 2
Differential Expression of Sox9 and Col2a1 in Nonskeletal Tissues
Tissues Sox9 Col2a1
7.5 dpc
Trophoblast, ectoplacental cone / 0
Visceral endoderm 0 Over cardiogenic mesoderm
Gut
Foregut portal endoderm Weak, patchy /
Hindgut endoderm Weak, patchy 0
Oesophagus
Epithelium / 0
Mesenchyme / 0
Hepatic diverticulum, / Patchy
septum transversum
Pancreas
Ductal epithelium / (14.5, 15.5 dpc) 0
Islet 0 / (14.5 dpc)
Intestine
Mucosa / (11.5±16.5 dpc) 0
Submucosa / (16.5 dpc) /
Root of mesentery / 0
Branchial arches
I and II arch mesenchyme 0 Weak
(Later in maxillary prominence)
III±VI arch / 0
Pharynx
Endoderm 0 /
Surface ectoderm / /
Lower lip
Mesenchyme 0 /
Alveolar ridge mesenchyme 0 /
Tongue mesoderm 0 / (distal tip)
Submandibular gland (duct) 0 /
Respiratory tract
Bronchial epithelium / /
Lung bud mesenchyme / 0
Limb bud
Surface ectoderm Weak Strong
Mesenchyme Preaxial  postaxial Restricted to
condensed mass
Urogenital structuresa
Genital ridge mesenchyme / (12.5 dpc) 0
Metanephric tubules / (12.5 dpc) {
Genital tubercle mesenchyme / (14.5 dpc) 0
Others
Tail tendon 0 /
Cornea 0 / (17.54 dpc)
Umbilical cord (membrane) / (11.5, 12.5 dpc) 0
Heart
Epimyocardium 0 /
Endocardium / 0
a Sex unknown.
it may be signi®cant that the terminal 20 amino acids of ther, the terminal 20 amino acids of mouse and human
SOX9 show 60% identity to the rainbow trout SOX8 se-SOX9 from mouse (Wright et al., 1995), human (Foster et
al., 1994; Wagner et al., 1994), chicken (GenBank Accession quence (Ito et al., 1995), whereas the remainder of the 83
amino acid region is only 18% identical. Many of the SOX9No. U12533), and rainbow trout (N. Takamatsu, personal
communication) show a higher degree of conservation than mutations in CD patients have been found to affect the
composition of the HMG box or to lead to severe truncationthe remainder of the terminal 83-amino-acid domain. Fur-
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or missense translation of the region downstream from the indirectly. The coexpression of SOX9 protein and Col2a1
mRNA in some nonchondrogenic tissues such as noto-HMG box (Foster et al., 1994; Wagner et al., 1994; Kwok et
al., 1995), con®rming the importance of both domains for chord, otic vesicle, and the developing CNS suggests that
positive regulation of Col2a1 by SOX9 may also occur inSOX9 function. Indeed, SuÈ dbeck et al. (1996) have demon-
strated that a SOX9 protein with an intact HMG box but these other tissues.
Despite the simplicity of a model in which SOX9 directlylacking an activation domain can act as a dominant negative
regulator of transcription. In view of the present results it or indirectly activates transcription of the Col2a1 gene, sev-
eral observations indicate that the transcriptional regula-will be important to determine the effect on Col2a1 tran-
scription and the developmental consequences of mimick- tion of Col2a1 is likely to be more complex. First, Sox9
expression was down-regulated in hypertrophic chondro-ing similar CD mutations in transgenic mice.
While the gross pattern of expression of Sox9 has been cytes and at sites of endochondral ossi®cation by 17.5±18.5
dpc, whereas Col2a1 expression declined to a lesser degree.described previously (Wright et al., 1995), a comprehensive
survey of the timing and sites of Sox9 mRNA and protein Second, Col2a1 expression in mature cartilage persisted be-
yond that of Sox9 mRNA and protein during later stages ofexpression during development has not been reported. The
results presented here suggest that, in addition to its major fetal development, indicating that SOX9 is not required for
the longer term maintenance of Col2a1 expression. Third,roles in chondrogenesis and skeletal development, Sox9 is
important for a variety of developmental processes, with the two genes show differential expression in several non-
chondrogenic tissues such as the heart and lung. Fourth,expression observed in the developing CNS, notochord,
lungs, heart, and urogenital system. The functional signi®- transcriptional activation by other HMG proteins such as
LEF-1 and SOX-2 requires cooperation of other factors (Carl-cance of these sites of expression is con®rmed by the obser-
vation that SOX9 mutations in CD patients commonly af- son et al., 1993; Giese and Grosschedl, 1993; Kamachi et
al., 1995; Yuan et al., 1995). These observations, and thefect a variety of nonskeletal organs such as the brain, tra-
cheopulmonary system, heart, and urinary tract (Lee et al., known involvement of multiple factor interactions in tran-
scriptional regulation (Tjian and Maniatis, 1994), suggest1972; Houston et al., 1983; Rodriguez, 1993) and frequently
result in XY sex reversal (Hovmoller et al., 1977; Tommerup that SOX9 also requires other tissue-speci®c cofactors for
transactivation of its target genes. The involvement of Sox9et al., 1993). In addition to genes important for skeletal
development, those involved in morphogenesis of other tis- in unrelated processes such as sex determination (Kent et
al., 1996; Morais da Silva et al., 1996) also points to varyingsues affected by CD, and in the testis-determining pathway,
must be considered potential targets for the SOX9 protein. combinations of SOX9 and other transcription factors to
achieve different regulatory functions. The determinationGiven that SOX9 can activate transcription and may func-
tion as a transcription factor, it is necessary to identify tar- of the precise molecular mechanisms by which SOX9 regu-
lates chondrogenesis and the identi®cation of potential co-get genes in order to clarify its developmental role. To date,
the only SOX protein for which a target has been identi®ed operating factors are important goals of future research.
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